Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crisaborole and PF-07038124 with NBUVB in Vitiligo
NCT05298033Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Sep 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AN2728 ointment vehicle and PF-07038124 in Vitiligo (6 arms), sponsored by University of Colorado Denver. Primary endpoint: Facial Vitiligo Area Scoring Index 50 at 24 weeks. Started Sep 2022; status: completed.
02
Drugs
AN2728 ointment vehiclePF-07038124
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT05298033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298033.